BusinessAXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related PsychosisBy Nasdaq OMXAug 2, 2017, 1:01 PM UTC
BusinessAXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg SyndromeBy Nasdaq OMXJul 20, 2017, 1:00 PM UTC
BusinessAXIM Biotech Holds Bi-Annual Board Meeting in New York City on July 8By Nasdaq OMXJul 12, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & CannabinoidsBy Nasdaq OMXJul 11, 2017, 1:00 PM UTC
BusinessCURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery PlatformBy Nasdaq OMXJul 5, 2017, 1:00 PM UTC
BusinessAXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid Addiction TreatmentBy Nasdaq OMXJun 23, 2017, 1:00 PM UTC
BusinessAXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency StudyBy Nasdaq OMXJun 19, 2017, 1:00 PM UTC
BusinessAXIM Biotech to Present at 2017 Marcum Microcap Conference in New York CityBy Nasdaq OMXJun 14, 2017, 1:00 PM UTC
